SynthesisOncotarget2017
Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis.PloS one · 2021Pooled it
- Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review.Frontiers in oncology · 2020Pooled it
- The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.International journal of molecular sciences · 2017Trial
- Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12R with an Ultra-Low-VAF SMAD4 Mutation: A Case Report and Mini-Review.Reports (MDPI) · 2026Article
- Article
- Article
- A Novel Diagnostic Model of Biomarkers in the Washing Fluid Obtained by EUS-FNA in Pancreatic Cancer.Journal of gastrointestinal cancer · 2025Article
- PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.Therapeutic advances in medical oncology · 2025Article
- Asymmetric crowders and membrane morphology at the nexus of intracellular trafficking and oncology.Mechanobiology in medicine · 2024Article
- The NF-κB/NUAK2 signaling axis regulates pancreatic cancer progression by targeting SMAD2/3.iScience · 2024Article
- Free energy calculations for membrane morphological transformations and insights to physical biology and oncology.Methods in enzymology · 2024Article
- Article
- Clinical Impact of Preoperative Biliary Drainage in Patients with Ductal Adenocarcinoma of the Pancreatic Head.Diagnostics (Basel, Switzerland) · 2023Article
- An 8q24 Gain in Pancreatic Juice Is a Candidate Biomarker for the Detection of Pancreatic Cancer.International journal of molecular sciences · 2023Article
- Tumor Stroma Area and Other Prognostic Factors in Pancreatic Ductal Adenocarcinoma Patients Submitted to Surgery.Diagnostics (Basel, Switzerland) · 2023Article
- SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4.Communications biology · 2022Article
- Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity.Cancers · 2022Review
- Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data.Nature reviews. Cancer · 2022Review
- The Role ofCancers · 2022Review
- TGFβ Signaling in the Pancreatic Tumor Microenvironment.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer mortality. Although advances have been made in understanding the pathogenesis of PDAC, the outcome still remains poor. The aim of this study is to conduct a meta-analysis to evaluate the precise association between SMAD4 loss and clinicopathological significance in PDAC. A literature search was made in PubMed, Web of Science, Google scholar, and EMBASE for related publications. The data were extracted and assessed by two reviewers independently. Analysis of pooled data was performed, Odds Ratio or Hazard Ratio with corresponding confidence intervals was calculated and summarized. 12 relevant articles were included for full review in detail and meta-analysis. The frequency of SMAD4 protein loss was significantly increased in PDAC than in nonmalignant pancreatic tissue, Odd Ratio was 0.05 with 95% confidence interval 0.01-0.23, p<0.0001. SMAD4 loss was significantly associated with poor overall survival in patients with PDAC, Hazard Ratio was 0.61 with 95% confidence interval 0.38-0.99, p=0.05. SMAD4 loss was not correlated with the size, grades, and lymph node metastasis of PDAC. In conclusion, SMAD4 is a biomarker for the diagnosis of PDAC. SMAD4 loss is significantly related to poor prognosis in patients with PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.